Bill Burns

Bill Burns is on the board of governors at the Wellcome Trust, the board of directors of Mesoblast, Shire, Vestergaard Frandsen and chairman of Masters Pharmaceuticals. He is also a member of Chugai International advisory board and a member of the scientific advisory board of the Center for Integrated Oncology at University Hospital Cologne. He served as chief executive officer of Roche Pharmaceuticals until 2010 and as a member of the Roche board of directors until 2013.

Pam Garside

Pam specializes in organizational strategy and development in healthcare, and is a fellow of the Judge Business School of the University of Cambridge. Pam founded and co-chairs The Cambridge Health Network, a membership group of senior players in UK health, in both the private and public sector. In 2016, Pam was named one of the 100 most influential leaders in health tech by Hot Topics.

Ed Godber

Ed Godber is Raremark's Entrepreneur-in-Residence, bringing over 20 years of experience working in academia, healthcare, life sciences and digital. He has previously served on the European Executive Team at GSK and the Executive Team at PatientsLikeMe.

In addition to his work with Raremark, Ed is President of PrecisionMedicine4Me, a patient-driven cancer company and an advisor to a number of digital technology companies, spanning behavioural change, wearables and AI.

Joel Haspel

Joel advises Raremark on its system architecture. He is currently VP of digital health life sciences at Clarivate Analytics and formerly a principal at GE Healthcare Finnamore. He has a wealth of experience working with the NHS, life science organizations and hospitals around the world on their technology transformation, solution design and delivery. Joel's areas of healthcare expertise include enterprise architecture, business intelligence, big data, translational research, precision medicine, IoT and mobile healthcare.

Alastair Kent OBE

Alastair Kent OBE is the chair of Rare Disease UK (RDUK), the national alliance for people with rare diseases and all who support them. Alastair has also served as director of Genetic Alliance UK, a national charity supporting all those affected by genetic conditions and an alliance of over 180 patient organisations. Alastair has worked in the field of genetic and rare disease healthcare for over 20 years. He represents the interests of patients on numerous platforms; as president of the European Genetic Alliances Network (EGAN), immediate past chair of the European Platform for Patient Organisations, Science and Industry (EPPOSI) and the EU Committee of Experts on Rare Diseases, among others. He has previously been a member of the Orphan Medicinal Products Committee and Committee for Advanced Therapies at the European Medicines Agency, and of the Human Genetics Commission.

Elia Stupka

Dr Elia Stupka is a Research Associate at Harvard Medical School in Boston where he heads up Data Science and Bioinformatics at the Dana-Farber Cancer Institute, bringing together research, clinical and operational data at one of the world’s leading cancer organizations to improve patient outcomes and the discovery of new treatments. Elia started his career on the first team to assemble the human genome in Cambridge, UK, in 2001. He then worked with Nobel Laureate Sydney Brenner to build the first genome research group in Singapore. Subsequently, Elia has worked at several key European research organizations, including Telethon in Italy, UCL in London and Boehringer Ingelheim Pharma, where he headed Genomics and Computational Biology. Elia helped to build the platform that supported the first successful stem cell gene therapy trials, co-developed with GSK, leading to the first commercialized gene therapy treatment Strimvelis.

Robert Thong

Robert Thong is a specialist in business-to-business partnering in life sciences. Over the past 27 years, he has worked with over 100 different life science and healthcare organisations across 12 countries in Europe, North America and Asia as a consultant, board-level adviser or P&L-responsible executive. He is a non-executive board member at Repositive, a genomics data discovery company, and also advises a number of healthcare start-ups. Robert's previous roles include Senior Vice President of the Life Sciences Group at Capgemini, Managing Director of the Healthcare Division at Datamonitor, European bioscience head at COBA and a non-executive board member at Alpharma, a US-listed mid-cap pharmaceutical group. Robert is the author of Biopharma R&D Partnerships:From David & Goliath to Networked R&D and is a judge for the annual pharmaceutical industry SCRIP Awards.